# Viatris Inc. (VTRS)

> VTRS · Nasdaq · Health care, pharmaceuticals · United States · US GAAP · Fiscal year ends December
>
> Latest report: Q3 FY2026, the quarter ended 30 September 2026, released 5 November 2026. Snapshot FY2026Q3_71d12bb4.

Page: https://annalist.io/company/viatris/

Identifiers: LEI 254900ZZTSW7NL773X71, CIK 0001792044

## Latest Figures

| Figure | Value | Exact value | Unit | Change | Period | Period end | Source documents |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Revenue, quarter | $3.7bn | 3749500000 | USD | −0.3% year on year | FY2026 Q3 | 2026-09-30 | 10-Q 2026-09 |
| Operating income, quarter | $262m | 261500000 | USD | +46.3% year on year | FY2026 Q3 | 2026-09-30 | 10-Q 2026-09 |
| Diluted EPS, quarter | −$0.28 | -0.28 | USD/shares | n.m. year on year | FY2026 Q3 | 2026-09-30 | 10-Q 2026-09 |
| Operating margin, last 4 quarters | 0.0% | -0.0312 | % | +18.7pp year on year | FY2026 Q3 | 2026-09-30 | 10-K 2025-12, 10-Q 2025-09, 10-Q 2026-03, 10-Q 2026-06, 10-Q 2026-09 |

- Operating margin: Operating income / revenue.

## Key Findings

Each finding is a sentence written by a fixed rule from the figures; the mark in brackets is how the finding moved against the report before.

- Revenue for the quarter ended 30 September 2026 was US$3.7 billion, 0.3% lower than in the same quarter a year earlier. [New in Q3 FY2026] Sources: 10-Q 2026-09, 10-Q 2025-09.
- The operating margin over the last 4 quarters was -0.0%, 18.7 percentage points higher than a year earlier. [Strengthened in Q3 FY2026] Sources: 10-K 2025-12, 10-Q 2025-09, 10-Q 2026-03, 10-Q 2026-06, 10-Q 2026-09, 10-K 2024-12, 10-Q 2024-09, 10-Q 2025-03, 10-Q 2025-06.
- Free cash flow over the last 4 quarters was US$2.1 billion. [Strengthened in Q3 FY2026] Sources: 10-K 2025-12, 10-Q 2025-09, 10-Q 2026-03, 10-Q 2026-06, 10-Q 2026-09.
- Net debt was US$11.5 billion at 30 September 2026, 4.1 times EBITDA over the last 4 quarters. [Weakened in Q3 FY2026] Sources: 10-Q 2026-09, 10-K 2025-12, 10-Q 2025-09, 10-Q 2026-03, 10-Q 2026-06.
- Debt was 4.7 times EBITDA over the last 4 quarters on reported figures, within the aggressive band of the S&P standard volatility table. The filings do not give the lease figures that the adjustment needs, so the ratio uses debt and EBITDA as reported. [Confirmed in Q3 FY2026] Sources: 10-Q 2026-09, 10-K 2025-12, 10-Q 2025-09, 10-Q 2026-03, 10-Q 2026-06.
- Cash, short-term investments and operating cash flow over the last 4 quarters equalled 2.0 times the sum of debt due within 12 months, capital expenditure and dividends. [Strengthened in Q3 FY2026] Sources: 10-Q 2026-09, 10-K 2025-12, 10-Q 2025-09, 10-Q 2026-03, 10-Q 2026-06.
- The Altman Z'' score for fiscal 2025 was 0.65, below the distress threshold of 1.10. [New in FY2025] Sources: 10-Q 2026-09, 10-K 2025-12.

## Fiscal Years

| Fiscal year | Year end | Item | Value | Exact value | Unit | Source documents |
| --- | --- | --- | --- | --- | --- | --- |
| FY2025 | 2025-12-31 | Revenue | $14.3bn | 14299900000 | USD | 10-K 2025-12 |
| FY2025 | 2025-12-31 | Operating income | −$2.7bn | -2663100000 | USD | 10-K 2025-12 |
| FY2024 | 2024-12-31 | Revenue | $14.7bn | 14739300000 | USD | 10-K 2025-12 |
| FY2024 | 2024-12-31 | Operating income | $10.1m | 10100000 | USD | 10-K 2025-12 |
| FY2023 | 2023-12-31 | Revenue | $15.4bn | 15426900000 | USD | 10-K 2025-12 |
| FY2023 | 2023-12-31 | Operating income | $766m | 766200000 | USD | 10-K 2025-12 |
| FY2022 | 2022-12-31 | Revenue | $16.3bn | 16262700000 | USD | 10-K 2024-12 |
| FY2022 | 2022-12-31 | Operating income | $1.6bn | 1614900000 | USD | 10-K 2024-12 |
| FY2021 | 2021-12-31 | Revenue | $17.9bn | 17886300000 | USD | 10-K 2023-12 |
| FY2021 | 2021-12-31 | Operating income | −$34.0m | -34000000 | USD | 10-K 2023-12 |

## Source Documents

- 10-Q 2026-09: Form 10-Q, period ended 30 September 2026, 5 Nov 2026 (https://www.sec.gov/Archives/edgar/data/1792044/000179204426000057/vtrs-20260930.htm)
- 10-K 2025-12: Form 10-K, period ended 31 December 2025, 26 Feb 2026 (https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/vtrs-20251231.htm)
- 10-Q 2025-09: Form 10-Q, period ended 30 September 2025, 6 Nov 2025 (https://www.sec.gov/Archives/edgar/data/1792044/000179204425000046/vtrs-20250930.htm)
- 10-Q 2026-03: Form 10-Q, period ended 31 March 2026, 7 May 2026 (https://www.sec.gov/Archives/edgar/data/1792044/000179204426000029/vtrs-20260331.htm)
- 10-Q 2026-06: Form 10-Q, period ended 30 June 2026, 6 Aug 2026 (https://www.sec.gov/Archives/edgar/data/1792044/000179204426000041/vtrs-20260630.htm)
- 10-K 2024-12: Form 10-K, period ended 31 December 2024, 27 Feb 2025 (https://www.sec.gov/Archives/edgar/data/1792044/000179204425000008/vtrs-20241231.htm)
- 10-Q 2024-09: Form 10-Q, period ended 30 September 2024, 7 Nov 2024 (https://www.sec.gov/Archives/edgar/data/1792044/000179204424000033/vtrs-20240930.htm)
- 10-Q 2025-03: Form 10-Q, period ended 31 March 2025, 8 May 2025 (https://www.sec.gov/Archives/edgar/data/1792044/000179204425000018/vtrs-20250331.htm)
- 10-Q 2025-06: Form 10-Q, period ended 30 June 2025, 7 Aug 2025 (https://www.sec.gov/Archives/edgar/data/1792044/000179204425000033/vtrs-20250630.htm)
- 10-K 2023-12: Form 10-K, period ended 31 December 2023, 28 Feb 2024 (https://www.sec.gov/Archives/edgar/data/1792044/000179204424000008/vtrs-20231231.htm)

## Reliability

- 331 checks compare these figures with other official figures; 0 failed.
- 2 values are withheld because the filings do not prove them; a withheld value is absent, never estimated.
- Every earlier snapshot stays published: https://annalist.io/api/v1/companies/viatris/snapshots.json

## Cite

Annalist, Viatris Inc., snapshot viatris/FY2026Q3_71d12bb4; <item>, <period>; source <document>. Link the page https://annalist.io/company/viatris/ and the source document of the figure.

A figure of a statement has an address of its own, which opens the page at that figure with its source documents: https://annalist.io/company/viatris/?fig=<statement>/<period>/<item>, for example https://annalist.io/company/viatris/?fig=pl_quarterly/FY2026%20Q3/revenue

## Full Data

- [Every statement, ratio and document of this snapshot (JSON)](https://annalist.io/api/v1/companies/viatris/snapshots/FY2026Q3_71d12bb4/info.json)
- [Latest snapshot, at an address that does not change (JSON)](https://annalist.io/api/v1/companies/viatris/latest.json)
- [Income statement, quarterly (CSV)](https://annalist.io/api/v1/companies/viatris/snapshots/FY2026Q3_71d12bb4/pl_quarterly.csv)
- [Income statement, annual (CSV)](https://annalist.io/api/v1/companies/viatris/snapshots/FY2026Q3_71d12bb4/pl_annual.csv)
- [Balance sheet, quarter end (CSV)](https://annalist.io/api/v1/companies/viatris/snapshots/FY2026Q3_71d12bb4/balance_sheet.csv)
- [Cash flow, quarterly (CSV)](https://annalist.io/api/v1/companies/viatris/snapshots/FY2026Q3_71d12bb4/cf_quarterly.csv)
- [Cash flow, annual (CSV)](https://annalist.io/api/v1/companies/viatris/snapshots/FY2026Q3_71d12bb4/cf_annual.csv)
- [Ratios, annual (JSON)](https://annalist.io/api/v1/companies/viatris/snapshots/FY2026Q3_71d12bb4/ratios/annual.json)
- [Ratios, quarterly (JSON)](https://annalist.io/api/v1/companies/viatris/snapshots/FY2026Q3_71d12bb4/ratios/quarterly.json)
- [Ratios, ttm (JSON)](https://annalist.io/api/v1/companies/viatris/snapshots/FY2026Q3_71d12bb4/ratios/ttm.json)
- [Key findings with their history (JSON)](https://annalist.io/api/v1/companies/viatris/findings.json)
- [New reports and findings (Atom feed)](https://annalist.io/company/viatris/feed.xml)
- [Excel workbook](https://annalist.io/company/viatris/viatris.xlsx)
- [Buyout model on these figures](https://annalist.io/deal-lab/buyout/viatris/)
- [Lenders, customers, suppliers and owners (brief in Markdown)](https://annalist.io/atlas/viatris/brief.md)
- [Lenders, customers, suppliers and owners (JSON)](https://annalist.io/api/v1/atlas/viatris.json)

## Peers

- [Bristol-Myers Squibb Company](https://annalist.io/company/bristol-myers-squibb/brief.md)
- [Pfizer Inc.](https://annalist.io/company/pfizer/brief.md)
- [AbbVie Inc.](https://annalist.io/company/abbvie/brief.md)
- [Side by side](https://annalist.io/compare/?c=viatris,bristol-myers-squibb,pfizer,abbvie)

---

Figures come from official filings and are provided as they are, without warranty of accuracy or completeness. They are not investment advice.